A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer

Summary

This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer.

Description

Eligibility

Age range

12+ years

Sex

All

Healthy volunteers

No

Interventions

• Biological
  Atezolizumab

  Given PO

• Biological
  Bevacizumab

  Given IV

• Procedure
  Biopsy Procedure

  Undergo biopsy

• Procedure
  Biospecimen Collection

  Undergo blood collection

• Procedure
  Bone Scan

  Undergo bone scan

• Procedure
  Computed Tomography

  Undergo CT without contrast

• Procedure
  Computed Tomography with Contrast

  Undergo CT with contrast

Locations (13)